Arvinas Inc (NASDAQ:ARVN)
| 42.55 Delayed Data As of Jul 01 |  +0.46 / +1.09%Today’s Change | 34.90 Today|||52-Week Range 108.47 | -48.20% Year-to-Date |
Latest ARVN News | Press Releases
| Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar? Jun 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 42.09 |
| Today’s open | 41.57 |
| Day’s range | 40.97 - 42.61 |
| Volume | 6,305 |
| Average volume (3 months) | 475,193 |
| Market cap | $2.4B |
Data as of 3:59pm ET, 07/01/2022
Growth & Valuation
| Earnings growth (last year) | -26.56% |
| Earnings growth (this year) | -16.00% |
| Earnings growth (next 5 years) | -13.13% |
| Revenue growth (last year) | +114.20% |
| P/E ratio | NM |
| Price/Sales | 87.94 |
| Price/Book | 3.11 |
Competitors
| ---- | ||
| FATEFate Therapeutics In... | +0.39 | +1.57% |
| TWSTTwist Bioscience Cor... | +2.14 | +6.12% |
| BCRXBioCryst Pharmaceuti... | +0.26 | +2.46% |
Data as of 4:00pm ET, 07/01/2022
Financials
| Next reporting date | August 9, 2022 |
| EPS forecast (this quarter) | -$1.09 |
| Annual revenue (last year) | $46.7M |
| Annual profit (last year) | -$191.0M |
| Net profit margin | -408.99% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters New Haven, Connecticut |
Forecasts
